Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4.

Antiviral therapy - 1 Jan 2010

Pramhas Sibylle, Homoncik Monika, Ferenci Peter, Ferlitsch Arnulf, Scherzer Thomas, Gangl Alfred, Peck-Radosavljevic Markus

Abstract excerpt

BACKGROUND: Levels of von Willebrand factor antigen (vWF-Ag) increase during combination antiviral therapy of chronic hepatitis C (CHC). The present study investigates the association between these changes in vWF-Ag levels and response to treatment. METHODS: Changes in levels of vWF-Ag on antivir...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Antiviral Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Predictive Value of Tests

Share to Recurrence

Share to Ribavirin

Share to von Willebrand Factor

Source

Identifiers

PMID: 20834095
DOI: 10.3851/IMP1654

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20834095-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4.PMID 20834095Read ↗

Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.Semantic proximity Read ↗

Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4.Semantic proximity Read ↗

Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4.Semantic proximity Read ↗

[Treatment of chronic hepatitis C virus infection. A study of best predictors for response].Semantic proximity Read ↗

Viral factors affecting the outcome of therapy for chronic hepatitis C.Semantic proximity Read ↗

Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study.Semantic proximity Read ↗

Pretreatment predictive factors for hepatitis C therapy outcome: relevance of anti-E1E2 antibodies compared to IP-10 and IL28B genotypes.Semantic proximity Read ↗

Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C.Semantic proximity Read ↗

Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection.Semantic proximity Read ↗

Early predictive efficacy of core antigen on antiviral outcomes in genotype 1 hepatitis C virus infected patients.Semantic proximity Read ↗

Early Viral Response Predicts the Efficacy of Antiviral Triple Therapy with Simeprevir, Peg-Interferon and Ribavirin in Patients Infected with Hepatitis C Virus Genotype 1.Semantic proximity Read ↗

Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.